|本期目录/Table of Contents|

复方苦参注射液联合TP方案对晚期肺癌患者疗效及预后的影响

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R]

期数:
2019年20期
页码:
3624-3627
栏目:
论着(胸部肿瘤)
出版日期:
2019-09-08

文章信息/Info

Title:
The influences of Compound Radix Sophorae Flavescentis Injection combined with TP regimen on curative effect and prognosis of patients with advanced lung cancer
作者:
李延玲1;?薛庆丽2;?王 迪3;?贺娟娟1;?李俊梅4;?王晓红5;?宋丽丽1;?郭瑞霞6
1.邯郸市人民医院呼吸内科;2.消化内科;3.神经内二科;4.口腔科;5.麻醉科,河北 邯郸 056001 6.邯郸市第一医院呼吸内科,河北 邯郸 056002
Author(s):
Li Yanling1;?Xue Qingli2;?Wang Di3;?He Juanjuan1;?Li Junmei4;?Wang Xiaohong5;?Song Lili1;?Guo Ruixia6
1.Department of Respiratory Medicine;2.Department of Digestive Internal Medicine;3.The Second Department of Neurology;4.Department of Stomatology;5.Department of Anesthesiology,Handan People's Hospital,Hebei Handan 056001,China;6.Department of Respiratory Medicine,Handan First Hospital,Hebei Handan 056002,China.
关键词:
复方苦参注射液;?TP方案;?晚期肺癌
Keywords:
Compound Radix Sophorae Flavescentis Injection;?TP scheme;?advanced lung cancer
分类号:
R734.2
DOI:
10.3969/j.issn.1672-4992.2019.20.017
文献标识码:
A
qq自动领红包软件:
目的:探究复方苦参注射液联合TP方案对晚期肺癌患者疗效及预后的影响。方法:选取2013年2月至2015年3月我院收治的100例经病理学或细胞学确诊为肺癌晚期患者作为研究对象,将其随机分为两组,每组各50例,两组均给予基础治疗,对照组进行TP方案化疗,研究组进行复方苦参注射液联合TP方案治疗。对比两组患者治疗有效率、疼痛指标、生活质量、不良反应发生情况,并随访3年观察患者预后情况。结果:研究组治疗有效率与对照组比较,差异无统计学意义(48.00% vs 30.00%,P>0.05);研究组患者疼痛指标显着低于对照组(P<0.05),生活质量提升的人数显着高于对照组(58% vs 28%,P<0.05);研究组患者腹泻、白细胞减少、血小板降低的发生率要显着小于对照组(P<0.05);对患者3年随访情况分析,研究组生存率显着高于对照组。结论:复方苦参注射液联合TP方案治疗肺癌晚期患者可有效减少患者疼痛情况,降低不良反应发生率,改善患者预后。
Abstract:
Objective:To explore the influences of Compound Radix Sophorae Flavescentis Injection combined with TP regimen on the curative effect and prognosis of patients with advanced lung cancer.Methods:100 patients with advanced lung cancer diagnosed by pathology or cytology from February 2013 to March 2015 were as the subjects and randomly divided into two groups,with 50 cases in each group.Both groups were given basic treatment,while the control group received TP regimen chemotherapy,and the study group received Compound Radix Sophorae Flavescentis Injection combined with TP regimen.The effective rate of treatment,pain index,quality of life and adverse reactions were compared between the two groups,and the prognosis was observed after 3 years follow-up.Results:The effective rate of the study group was 48.00%,which was not significantly different from 30.00% of the control group (P>0.05).The pain index of the study group was significantly lower than that of the control group (P<0.05),and the number of life quality improvement was 58%,which was also significantly higher than 28%of the control group (P<0.05).The incidence rates of diarrhea,leukopenia and thrombocytopenia in the study group were significantly lower than those in the control group (P<0.05).Conclusion:Compound Radix Sophora Flavescentis Injection combined with TP regimen in the treatment of advanced lung cancer patients can effectively reduce pain,reduce the incidence of adverse reactions,improve the prognosis of patients.

参考文献/References

[1]WANG LM,LIU Y,XU S.Analysis of prognostic and recurrence factors in stage Ⅲ non-small cell lung cancer[J].Chinese Journal of Cancer Prevention and Treatment,2017,24(21):1534-1538.[王黎明,刘洋,许顺.Ⅲ期非小细胞肺癌手术治疗患者预后因素分析[J].中华肿瘤防治杂志,2017,24(21):1534-1538.]
[2]SHANG CC,ZHANG L.Advances in immunotherapy for non-small cell lung cancer[J].Chin J Clinical Oncol,2018,45(04):205-208.[尚聪聪,张力.非小细胞肺癌免疫治疗进展[J].中国肿瘤临床,2018,45(04):205-208.]
[3]YUAN Y.Anti-tumor effect of traditional Chinese medicine on immunologic intervention of T lymphocytes[J].Chinese Journal of Cancer Biotherapy,2017,24(2):189-193.[袁野.中药对T细胞免疫干预的抗肿瘤作用[J].中国肿瘤生物治疗杂志,2017,24(2):189-193.]
[4]LI QY,ME HY.Research progress on risk factors of lung cancer[J].China Cancer,2016,25(10):782-786.[李媛秋,么鸿雁.肺癌主要危险因素的研究进展[J].中国肿瘤,2016,25(10):782-786.]
[5]Stracquadanio G,Wang X,Wallace MD,et al.The importance of p53 pathway genetics in inherited and somatic cancer genomes[J].Nature Reviews Cancer,2016,16(4):251-265.
[6]Czarnecka KH,Migdalska-Sek M,Domańska D,et al.FHIT promoter methylation status,low protein and high mRNA levels in patients with non-small cell lung cancer[J].Int J Oncol,2016,49(3):1175-1184.
[7]Davidson SM,Papagiannakopoulos T,Olenchock BA,et al.Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer[J].Cell Metabolism,2016,23(3):517-528.
[8]ZHANG YJ,XU F,HAN JC,et al.Clinical trial of pemetrexed combined with paclitaxel and cisplatinin the treatment of non small-cell lung cancer[J].Chin J Clin Pharmacol,2016,32(15):1396-1399.[张雅军,徐锋,韩纪昌,等.培美曲塞联合紫杉醇和顺铂治疗非小细胞肺癌的临床研究[J].中国临床药理学杂志,2016,32(15):1396-1399.]
[9]Hainsworth JD,Meluch AA,Mcclurkan S,et al.Induction paclitaxel,carboplatin,and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer:A phase II trial of the Minnie Pearl Cancer Research Network[J].Cancer Journal,2016,8(4):311-321.
[10]Chen Y,Li J,Chen S,et al.Nab-paclitaxel in combination with cisplatin versus docetaxel plus cisplatin as first-line therapy in non-small cell lung cancer[J].Scientific Reports,2017,7(1):10760-10767.
[11]Yu WK,Wang Z,Fong CC,et al.Chemoresistant lung cancer stem cells display high DNA repair capability to remove cisplatin-induced DNA damage[J].British Journal of Pharmacology,2017,174(4):302-313.
[12]Amable L.Cisplatin resistance and opportunities for precision medicine[J].Pharmacological Research,2016(106):27-36.
[13]Sugiyama T,Mizuno M,Aoki Y,et al.A single-arm study evaluating bevacizumab,cisplatin,and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer[J].Japanese Journal of Clinical Oncology,2017,47(1):39-46.
[14]Wu YL,Zhou C,Hu CP,et al.Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR,mutations (LUX-Lung 6):An open-label,randomised phase 3 trial[J].Lancet Oncology,2014,15(2):213-222.
[15]HUANG YX,GUO YM,SANG XX,et al.Systematic review of efficacy compound kushen injectionin relieving cancer-related pain[J].Chinese Journal of Experimental Traditional Medical Formulae,2016,22(2):172-179.[黄奕雪,郭玉明,桑秀秀,等.复方苦参注射液治疗癌性疼痛的系统评价[J].中国实验方剂学杂志,2016,22(2):172-179.]
[16]QI HW.Clinical study of compound matrine injection combined with chemotherapy in the treatment of patients with advanced colon cancer[J].Liaoning Journal of Traditional Chinese Medicine,2016,43(3):547-548.[祁宏伟.复方苦参注射液联合化疗治疗晚期结肠癌临床研究[J].辽宁中医杂志,2016,43(3):547-548.]

备注/Memo

备注/Memo:
河北省中医药管理局科研计划项目(编号:2019389)
更新日期/Last Update: 1900-01-01